{"organizations": [], "uuid": "14cb9eb01c9be61e7be89b0f32d6e769640f5627", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/03/business-wire-resolutions-of-the-annual-combined-shareholders-meeting-of-sartoriusastedim-biotech-s-a.html", "country": "US", "domain_rank": 767, "title": "Resolutions of the Annual Combined Shareholders' Meeting of Sartorius Stedim Biotech S.A.", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T17:30:00.000+03:00", "replies_count": 0, "uuid": "14cb9eb01c9be61e7be89b0f32d6e769640f5627"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/03/business-wire-resolutions-of-the-annual-combined-shareholders-meeting-of-sartoriusastedim-biotech-s-a.html", "ord_in_thread": 0, "title": "Resolutions of the Annual Combined Shareholders' Meeting of Sartorius Stedim Biotech S.A.", "locations": [], "entities": {"persons": [{"name": "kappich", "sentiment": "none"}, {"name": "arnold picot", "sentiment": "none"}, {"name": "lothar kappich", "sentiment": "none"}, {"name": "anne-marie graffin", "sentiment": "none"}, {"name": "susan dexter", "sentiment": "none"}], "locations": [{"name": "aubagne", "sentiment": "none"}, {"name": "france", "sentiment": "none"}, {"name": "aubagne", "sentiment": "none"}, {"name": "paris", "sentiment": "none"}], "organizations": [{"name": "sartorius stedim biotech s.a.", "sentiment": "negative"}, {"name": "sartorius stedim biotech group", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "AUBAGNE, France--(BUSINESS WIRE)-- Regulatory News:\nAt today’s Annual General Shareholders' Meeting (AGM) of Sartorius Stedim Biotech S.A. (Paris:DIM) in Aubagne, France, shareholders passed the resolution to pay a dividend of €0.46 per share for fiscal 2017. The previous year’s dividend was €0.42 per share. The total profit distributed will therefore rise by 9.6% from €38.7 million to €42.4 million.\nFurthermore, the Annual General Shareholders´ Meeting ratified the cooptation of Dr. Lothar Kappich as Director of the company. In September 2017, Lothar Kappich replaced Professor Arnold Picot, who had passed away on July 9, 2017. Kappich’s directorship will last for one more year. In addition, the Annual General Shareholders’ Meeting approved the renewal of the appointments of Susan Dexter and Anne-Marie Graffin as Directors, each for a three-year term.\nThis press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.\nA profile of Sartorius Stedim Biotech\nSartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is Quote: d on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of €1,081.0 million.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180403005829/en/\nSartorius Stedim Biotech S.A.\nPetra Kirchhoff\nVice President of Corporate Communications and IR\n+49 (0)551.308.1686\npetra.kirchhoff@sartorius.com\nwww.sartorius-stedim.com\nSource: Sartorius Stedim Biotech S.A.", "external_links": ["https://www.businesswire.com/news/home/20180403005829/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sartorius-stedim.com&esheet=51782451&lan=en-US&anchor=www.sartorius-stedim.com&index=1&md5=78694e2dc7c78bbfdb2be620c8b5ef93"], "published": "2018-04-03T17:30:00.000+03:00", "crawled": "2018-04-03T19:21:43.004+03:00", "highlightTitle": ""}